1. Home
  2. TNGX vs CHH Comparison

TNGX vs CHH Comparison

Compare TNGX & CHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

N/A

Current Price

$23.48

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Logo Choice Hotels International Inc.

CHH

Choice Hotels International Inc.

N/A

Current Price

$117.42

Market Cap

4.7B

ML Signal

N/A

Company Overview

Basic Information
Metric
TNGX
CHH
Founded
2014
1939
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.7B
IPO Year
2020
1997

Fundamental Metrics

Financial Performance
Metric
TNGX
CHH
Price
$23.48
$117.42
Analyst Decision
Strong Buy
Hold
Analyst Count
13
18
Target Price
$47.09
★ $115.94
AVG Volume (30 Days)
★ 4.4M
527.8K
Earning Date
11-17-2026
11-02-2026
Dividend Yield
N/A
★ 0.97%
EPS Growth
26.89
★ 27.42
EPS
N/A
★ 3.12
Revenue
$62,384,000.00
★ $1,596,793,000.00
Revenue This Year
N/A
$2.96
Revenue Next Year
N/A
$2.66
P/E Ratio
★ N/A
$37.40
Revenue Growth
★ 48.29
0.75
52 Week Low
$7.37
$84.04
52 Week High
$34.39
$123.82

Technical Indicators

Market Signals
Indicator
TNGX
CHH
Relative Strength Index (RSI) 45.45 66.40
Support Level $20.46 $104.17
Resistance Level $25.68 $123.82
Average True Range (ATR) 1.68 3.68
MACD -0.19 0.73
Stochastic Oscillator 8.61 86.47

Price Performance

Historical Comparison
TNGX
CHH

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About CHH Choice Hotels International Inc.

At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.

Share on Social Networks: